1. Scrip
  2. >>Business

One To Watch: Ruling On AZ’s First-In-Class Anemia Drug Roxadustat Expected Shortly

Label Warning Will Be Key

 
• By Andrew McConaghie

AstraZeneca is in pole position to open up the HIF-PH inhibitor market – but GSK has a rival in the wings.

Blood transfusion
Roxadustat has been developed for patients with chronic kidney disease-induced anemia, regardless of whether they dependent on blood transfusions or not.

A decision from the US Food and Drug Administration on AstraZeneca’s roxadustat for patients with anemia of chronic kidney disease (CKD) is expected shortly, the ruling possibly coming well ahead of its PDUFA deadline of 20 March.

Industry analysts are predicting peak annual sales of $2bn or more for roxadustat, but its success will hinge on whether...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By Mandy Jackson

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.